Giovanni Caforio Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 2 days, 4 hours ago
Giovanni Caforio has an estimated net worth of at least $52.8 million*, as of Sept. 3, 2025. They own 432,266 shares of BMY stock. They have sold 445,000 shares of BMY stock since 2021, for an estimated $32.2 million.
Giovanni Caforio $BMY SEC Form 4 Insider Trading
Giovanni Caforio has filed a total of 8 insider trades in $BMY since 2021. Their most recent trade was a sale of 240,000 shares, made on Feb 06, 2023. Their largest trade was a sale of 240,000 shares, made on Feb 06, 2023. We estimate that they now own 432,266 shares of $BMY, worth an estimated $20.6 million.
Insider Trading at $BMY
There have been a total of 45 insider trades reported at $BMY since 2021, with 23,474 shares purchased and 1.4 million shares sold. The most active insider traders in $BMY stock have been Giovanni Caforio, Rupert Vessey, and David V Elkins. The most recent trade was a sale of 56,000 shares reported by David V Elkins (EVP, Chief Financial Officer), made on Sep 02, 2025.
History of Insider Stock Trades by Giovanni Caforio
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
BMY
|
Sale | 240,000 | Feb 06, 2023 | Feb. 8, 2023, 9:09 p.m. |
|
BMY
|
Sale | 25,000 | Sep 20, 2022 | Sept. 22, 2022, 5:12 p.m. |
|
BMY
|
Sale | 50,000 | Sep 15, 2022 | Sept. 16, 2022, 5:12 p.m. |
|
BMY
|
Sale | 30,000 | Jun 13, 2022 | June 14, 2022, 5:58 p.m. |
|
BMY
|
Sale | 25,000 | Mar 21, 2022 | March 23, 2022, 7:43 p.m. |
|
BMY
|
Sale | 30,000 | Feb 24, 2022 | Feb. 27, 2022, 8 p.m. |
|
BMY
|
Sale | 25,000 | Sep 20, 2021 | Sept. 21, 2021, 8 p.m. |
|
BMY
|
Sale | 20,000 | Aug 02, 2021 | Aug. 3, 2021, 8 p.m. |
$BMY Executives and Stock Owners with Insider Trades
-
Giovanni Caforio, Board Chair and CEO
-
Rupert Vessey, EVP, Research & Early Dev.
-
David V Elkins, EVP, Chief Financial Officer
-
Autenried Paul Von, EVP, Chief Information Officer
-
Ann Powell, EVP, Chief Human Resources
-
Samit Hirawat, EVP,Chief Med.Offr.,Drug Dev.
-
Christopher S. Boerner, Chief Executive Officer
-
Sandra Leung, EVP, General Counsel
-
Christopher S. Boerner, EVP, Chief Commercial Officer
-
Benjamin Hickey, President, RayzeBio Org.
-
Giovanni Caforio, Chairman and CEO
-
Karen Murphy Santiago, SVP & Controller
-
Phil M Holzer, SVP and Controller
-
Rupert Vessey, EVP & President, Research
-
Bartie Wendy Short, EVP, Corporate Affairs
-
Robert M Plenge, EVP, Chief Research Officer
-
Adam Dubow, SVP,ChiefCompliance&EthicsOff.
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.